Aug. 5 at 11:12 AM
$ANVS
potential)
Purchased at
$14 billion, price reflects blockbuster expectations and strategic neuroscience expansion.
AP News
Wikipedia
4. AbbVie — Cerevel Therapeutics (tavapadon, emraclidine)
Acquired for
$8.7 billion, based on promising Phase 3-stage CNS drugs like tavapadon (Parkinson’s) and Alzheimer’s-related assets.
Wikipedia
5. Merck — Mitokinin / PINK1‑targeting Parkinson's program
Deal initiated with
$110 million upfront plus up to
$545 million in milestones, even though prior to Phase 3.
BioPharma Dive
📌 Implications for Buntanetap
With Phase 3 pivotal trials in both Alzheimer's and Parkinson’s underway, buntanetap aligns most closely with mid‑ to late-stage neurodegenerative assets entering Phase III that command valuations ranging from
$500 million to multi‑billion dollar, depending on clinical expectations and commercial potential.
⚖️ Comparative Valuation Estimate for Buntanetap
Comparable Scenario Indicative Valuation Range
Sanofi-Vigil (Phase II
